2 Result: Nasdaq:TARS
Buy Ratings: TARS, VICR, SNDX, ENLC, AMZN, UFPT, PEN - Key Upside Potential
June 26th, 2023
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company specializing in ophthalmic therapeutics, has been maintained at a Buy rating by HC Wainwright & Co., who raised the price target from $40 to $44. $TARS closed at $17.15. Read more
Market Buzz: Bullish Narrative for Liquid Media, Tarsus Pharma, Vertiv, and Neogen
June 17th, 2023
Shares of Liquid Media Group Ltd. (Nasdaq: YVR) experienced a notable surge of over 11% in after-hours trading Friday as the company revealed the sale of its wholly-owned subsidiary, IndieFlix Group, for a total purchase price of US$1.2 million. T. Read more
Want To Find Some News?
News By Industries
Recent Post
-
September 23rd, 2026
FTC Endorses Education Department Proposal to Expand Higher Education Accreditation Options
September 22nd, 2026September 18th, 2026FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026
Member Login